Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safely and clinical activity in patients with moderate to severe Crohn's disease

Hommes, D. W.; Mikhajlova, T. L.; Stoinov, S.; Štimac, D.; Vucelic, B.; Lonovics, J.; Zákuciová, M.; D'Haens, G.; Van Assche, G.; Ba, S.; Lee, S.; Pearce, T.
August 2006
Gut;Aug2006, Vol. 55 Issue 8, p1131
Academic Journal
Introduction: Interferon γ is a potent proinflammatory cytokine implicated in the inflammation of Crohn's disease (CD). We evaluated the safety and efficacy of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe CD. Methods: A total of 133 patients with Crohn's disease activity index (CDAI) scores between 250 and 450, inclusive, were randomised to receive placebo or fontolizumab 4 or 10 mg/kg. Forty two patients received one dose and 91 patients received two doses on days 0 and 28. Investigators and patients were unaware of assignment. Study end points were safety, clinical response (decrease in CDAI of 100 points or more), and remission (CDAI ⩽ 150). Results: There was no statistically significant difference in the primary end point of the study (clinical response) between the fontolizumab and placebo groups alter a single dose at day 28. However, patients receiving two doses of fontolizumab demonstrated doubling in response rate at day 56 compared with placebo: 32% (9/28) versus 69% (22/32, p=0.02) and 67% (21/31, p=0.03) for the placebo, and 4 and 10 mg/kg fontolizumab groups, respectively. Stratification according to elevated baseline C reactive protein levels resulted in a decreased placebo response and pronounced differences in clinical benefit. Two grade 3 adverse events were reported and were considered to be related to CD. One death (during sleep) and one serious adverse event (an elective hospitalisation) occurred, both considered unrelated. Conclusion: Treating active CD with fontolizumab was well tolerated and resulted in increased rates of clinical response and remission compared with placebo.


Related Articles

  • Inflammatory Bowel Diseases.  // Current Medical Literature: Gastroenterology;2009, Vol. 28 Issue 3, p70 

    This article presents updates on studies related to inflammatory bowel diseases (IBD). A study found that infliximab can be safely administered to most of the patients with IBD. One study found that endoscopic recurrence rates in patients who underwent surgery for Crohn's disease were...

  • Sargramostim in patients with Crohn’s disease: results of a phase 1—2 study. Takazoe, Masakazu; Matsui, Toshiyuki; Motoya, Satoshi; Matsumoto, Takayuki; Hibi, Toshifumi; Watanabe, Mamoru // Journal of Gastroenterology;2009, Vol. 44 Issue 6, p535 

    We aimed to assess the tolerability, pharmacokinetics, safety, and efficacy of sargramostim in Japanese patients with active Crohn’s disease (CD). Patients with moderately to severely active CD were enrolled. Step 1 was an open-label, phase 1 study of 2 μg/kg per day sargramostim...

  • Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's disease. Cassinotti, Andrea; Ardizzone, Sandro; Porro, Gabriele Bianchi // Core Evidence;2007, Vol. 2 Issue 3, p209 

    Introduction: Crohn's disease (CD) is a chronic inflammatory bowel disease characterized by a relapsing/remitting course with transmural inflammation of potentially any section of the digestive tract. Certolizumab pegol (CZP) is a pegylated Fc-free Fab' fragment of a humanized anti-TNF-alfa...

  • Steroid resistance in IBD: how big is the problem?  // Gut;Nov2006, Vol. 55 Issue 11, p1639 

    The article presents the study on the resistance of steroid in inflammatory bowel disease. Patients with ulcerative colitis and Crohn disease were evaluated, who were diagnosed at the Western General Hospital in Edinburgh, Scotland. The results show that corticosteroids are used for more often...

  • Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Annaházi, Anita; Molnár, Tamás // Gastroenterology Research & Practice;6/14/2015, Vol. 2015, p1 

    Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic inflammatory disorders, which require long term treatment to achieve remission and to prevent relapses and cancer. While current therapies are effective in most cases, they can have rare but serious side effects and are often...

  • Crohn's disease: why the disparity in mortality? Loftus Jr., E. V. // Gut;Apr2006, Vol. 55 Issue 4, p447 

    The article comments on a study conducted by F.L. Wolters and colleagues titled "Crohn's Disease: Increased Mortality 10 Years After Diagnosis in a Europe-Wide Population-Based Cohort." The author cites the strengths and weaknesses of the EC-IBD mortality study. He also compares the EC-IBD study...

  • Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease.  // Inflammatory Bowel Disease Monitor;Apr2009, Vol. 10 Issue 2, p63 

    In this articles, the authors comment on the evaluation of the predictors of adherence to medical management in 120 black and 115 white with inflammatory bowel disease (IBD) patients from a single outpatient clinic in Baltimore, Maryland.

  • Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center.  // Inflammatory Bowel Disease Monitor;2010, Vol. 11 Issue 2, p84 

    The article looks into the result of the study which investigates the significant changes of the rate and indication for small-bowel resection presented on the Crohn's disease patients at the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania.

  • Inflammatory Bowel Diseases.  // Current Medical Literature: Gastroenterology;2009, Vol. 28 Issue 2, p43 

    The article discusses several research on inflammatory bowel diseases. The effectiveness of maintenance treatment of collagenous colitis with oral budesonide was investigated by two studies, one of which took place in Germany while the other was conducted in Denmark. A study in Cork, Ireland...


Read the Article


Sign out of this library

Other Topics